<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122716">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01908972</url>
  </required_header>
  <id_info>
    <org_study_id>12172-MM-231</org_study_id>
    <nct_id>NCT01908972</nct_id>
  </id_info>
  <brief_title>The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma</brief_title>
  <official_title>The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficiency of Propranolol as an
      initial treatment for pediatric hemangioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Randomized (A group : propranolol, B group : prednisolone)

        -  A group : 3 days admission and medication for 16 weeks

        -  B group : medication for 16 weeks without admission

        -  Hemangioma volume comparison by using MRI

        -  other measurement and drug adverse reaction monitoring
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hemangioma volume measured by MRI or SONO</measure>
    <time_frame>After 16weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>We compared hemangioma volume measured by MRI or SONO, before and 16 weeks after medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size changes from baseline</measure>
    <time_frame>After 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the horizontal and vertical size (2-dimension)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate change from Baseline at 16 weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Heart rate fall to &lt;70% of acceptable age related minimum post-dose with child awake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in color</measure>
    <time_frame>After 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Red/Purple/Blue/Gray/Apricot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Size of Ulceration</measure>
    <time_frame>After 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the horizontal and vertical size (2-dimension)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether or not Re-epithelized in 16weeks</measure>
    <time_frame>After 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stop time of proliferation</measure>
    <time_frame>After 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time when hemangioma stop growing within 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of regression</measure>
    <time_frame>Within 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time when hemangioma decreased to 75% of baseline size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance within 16 weeks</measure>
    <time_frame>After 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Check the number of having drugs and skip time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in systolic blood pressure at 16 weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Systolic blood pressure fall of &gt;25% of baseline postdose with child awake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Glucose level at 16 weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Check the Glucose level whether to fall (to &lt;50mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether the facial edema occurs within 16 weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether growth retardation occurs within 16 weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>When the subject do not grow in 16 weeks at all.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether the Gastroesophageal reflux occurs within 16 weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse drug reaction</measure>
    <time_frame>up to 16weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All symptoms associated adverse drug reaction will be checked</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Hemangioma</condition>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>2mg/kg/day for 16weeks</description>
    <arm_group_label>Prednisolone</arm_group_label>
    <other_name>steroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>2mg/kg/day for 16weeks</description>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>beta-blocker</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemangioma patient ( 0 ~ 9 months old)

          -  No treatment before

          -  10 ~ 20 % volume increase in 2 ~ 4 weeks

          -  Hemangioma that caused organ function

          -  Hemangioma that will cause aesthetic problem

        Exclusion Criteria:

          -  Cardiovascular disease (impossible to use propranolol)

          -  Drug adverse reaction or allergy history (propranolol, steroid)

          -  Bradycardia, Atrioventricular block, atrial block

          -  Cardiogenic Shock

          -  Right heart failure (pulmonary hypertension)

          -  Congestive heart failure

          -  Hypotension

          -  Peripheral nerve disease (moderate)

          -  Angina

          -  Hormone deficiency patient

          -  Pulmonary disease (asthma)

          -  diabetic ketoacidosis

          -  laser treatment history
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>9 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Duk Park, MD, Ph D</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Hyun Choi, MD, Ph D</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae Hyun Choi, MD, Ph D</last_name>
    <phone>82-2-2072-1978</phone>
    <email>psthchoi@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jae Hoon Jeong, MD</last_name>
    <phone>82-31-787-7225</phone>
    <email>psdrj2h@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seould National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Hyun Choi, MD, Ph D</last_name>
      <phone>82-2-2072-1978</phone>
      <email>psthchoi@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemangioma</keyword>
  <keyword>Propranolol</keyword>
  <keyword>prednisolone</keyword>
  <keyword>steroid</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
